SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending following reported 700% year-over-year revenue growth, fueled by recent expanded global approvals for its cancer therapies in the EU and Saudi Arabia. The community is buzzing with anticipation of a significant short squeeze and further label expansions, highlighting the immense potential of its diverse immunotherapy platform.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending after its CagriSema weight-loss drug trial achieved 23% weight loss but missed its primary endpoint of non-inferiority compared to Eli Lilly's tirzepatide, causing a significant stock drop. The community is debating whether this market reaction is an overblown response to a minor efficacy difference, creating a buying opportunity, or if it signals a tougher competitive landscape against its rival.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is buzzing after securing FDA approval for BYSANTI, its new drug for bipolar I disorder and schizophrenia, a development the community sees as a significant re-rating catalyst due to its New Chemical Entity status and patent protection extending to 2044. This long-term exclusivity is fueling widespread speculation about potential buyout offers from major pharmaceutical companies and the stock's short squeeze potential, even as some investors eye commercial launch timelines and possible dilution.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera (ATOM) is trending as a recent direct stock offering at $5 sparks debate, with bulls viewing it as a strategic move to fund game-changing MST technology for AI and data centers, while bears voice skepticism over dilution given the company's pre-revenue status and historical performance.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors digest news of a significant stock sale filing from Trump's trust, fueling community discussions around potential dilution and the company's highly scrutinized financial viability. There is ongoing anticipation of upcoming reports and updates regarding a debated 'fusion deal' amidst concerns about its fundamental value.

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Redwood City MD.

Arcellx Inc

Arcellx ($ACLX) is surging after Gilead Sciences ($GILD) announced its acquisition for $115 per share in cash, valuing the cancer therapy developer at up to $7.8 billion. The biotech community is enthusiastically discussing the significant premium and the potential for increased M&A activity in the oncology sector.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending on the heels of its latest financial results, which exceeded expectations, and significant advancements across its neuroscience pipeline, including the priority review of AXS-05 for Alzheimer's disease agitation. Investors are keenly focused on the company's strong commercial momentum and path to cash flow positivity, with numerous analyst upgrades reflecting bullish sentiment despite initial market reactions.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is surging on overwhelmingly positive Phase 2 S-OLARIS trial results for sonelokimab in axSpA, which demonstrated exceptional efficacy and potential disease-modifying effects, further bolstered by a robust financial outlook. The community is actively discussing the drug's best-in-class potential, its significant market opportunity, and a major institutional buy-in, fueling expectations for a substantial re-evaluation and potential short squeeze ahead of its Investor Day.

Domino's Pizza, Inc. engages in the management of a network of company-owned and franchise-owned pizza stores. It operates through the following segments: U.S. Stores, International Franchise, and Supply Chain. The U.S. Stores segment consists primarily of franchise operations. The International Franchise segment comprises a network of franchised stores. The Supply Chain segment manages regional dough manufacturing and food supply chain centers. The company was founded by James Monaghan and Thomas Stephen Monaghan in 1960 and is headquartered in Ann Arbor, MI.

Dominos Pizza Inc

Domino's is trending after reporting Q4 earnings with strong revenue and a dividend increase, though an EPS miss has fueled community debate over its "Hungry for MORE" strategy driving market share gains against competitive and macro pressures.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble (RUM) is trending due to its pending acquisition of Northern Data, which aims to boost its cloud capacity for government and AI, and significant investment pledges from Tether. Community sentiment is largely focused on a potential short squeeze driven by high short interest, though many also voice skepticism regarding sustained price performance amidst new initiatives like Rumble Shorts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NexGen Energy $NXE Shares Sold by MMCAP International Inc. SPC

MMCAP International Inc. SPC lessened its stake in shares of NexGen Energy (NYSE:NXE - Free Report) by 97.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and...

NexGen Energy (NXE) Projected to Post Earnings on Monday

NexGen Energy (NYSE:NXE) will be releasing its Q4 2025 earnings before the market opens on Monday, March 2. (View Earnings Report at...

Big Tech Turns To Uranium As Data Center Power Demand Soars

Big Tech Turns To Uranium As Data Center Power Demand Soars Big Tech is considering supporting new uranium mining projects as companies need additional reliable power capacity for their huge data...

Beyond Tech: The Hidden Winners of the AI Energy Boom

Beyond Tech: The Hidden Winners of the AI Energy Boom Beyond Tech: The Hidden Winners of the AI Energy Boom PR Newswire VANCOUVER, BC, Feb. 17, 2026 Issued on behalf of Eagle Energy Metals...

NexGen Energy (TSE:NXE) Given New C$22.00 Price Target at Stifel Nicolaus

Stifel Nicolaus raised their target price on NexGen Energy from C$20.00 to C$22.00 and gave the stock a "buy" rating in a research report on Wednesday...

Alps Advisors Inc. Sells 1,609,680 Shares of NexGen Energy $NXE

Alps Advisors Inc. reduced its stake in NexGen Energy (NYSE:NXE - Free Report) by 9.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange...

Old West Investment Management LLC Buys 114,971 Shares of NexGen Energy $NXE

Old West Investment Management LLC increased its stake in shares of NexGen Energy (NYSE:NXE - Free Report) by 4.5% during the 3rd quarter, according to its most recent Form 13F filing with the...

NexGen Energy (NYSE:NXE) Sees Unusually-High Trading Volume - Should You Buy?

NexGen Energy (NYSE:NXE) Sees Strong Trading Volume - Here's What Happened...

NexGen Energy (TSE:NXE) Price Target Raised to C$19.00 at National Bankshares

National Bankshares upped their price objective on NexGen Energy from C$18.00 to C$19.00 and gave the stock an "outperform" rating in a report on Friday...

<ul class="summary-bullets"><li>Culper added that the company’s targeted peak annual uranium production of 29.7M lbs is “impossible to achieve.”</li><li>Culper also said that it believes NexGen's capital costs and construction timelines remain “materially understated.”</li><li>The firm estimates that company insiders and their affiliates have sold $275 million in stock in the past 3 years alone.</li></ul> Shares of NexGen Energy Ltd. (NXE) slumped as much as 10% on Friday after Culper Research announced a short position in the Canadian-based uranium exploration and development company.Culper <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://culperresearch.com/wp-content/uploads/2026/02/Culper_NXE_2-6-2026.pdf">alleged</a> that the net present value (NPV) of NexGen’s Rook I project is overstated by 43% to 62% and the company is “ultimately an insider enrichment scheme with substantial downside.”It also added that the company’s targeted peak annual uranium production of 29.7M lbs is “impossible to achieve.”<h2 class="st-heading-2">Other Allegations</h2>The Canadian company is focused on developing the Rook I Project in Saskatchewan’s Athabasca basin into the largest, low-cost producing uranium mine globally.According to Culper, Rook I’s claimed C$6.3 billion NPV is underpinned by ultra-high-grade pods discovered a decade ago, by a single contractor, analyzed at a single laboratory. There was no twin hole drilling or secondary lab analysis, it said.Despite uncovering supposedly the greatest uranium asset on the planet, NexGen’s original discovery team left the company, Culper said, while adding that this is “pretty unusual."Culper also said that it believes NexGen's capital costs and construction timelines remain “materially understated.”“The Company’s current 4-year construction timeline assumes near-flawless execution of a novel, complex underground mine plan at a remote, infrastructure-poor site in northern Saskatchewan,” it wrote.However, CEO Leigh Curyer has “serially overpromised,” Culper noted, claiming as early as 2016 that NexGen would be in production “post-2020.” The Company now promises to be producing by 2030.“We believe NexGen is, at its core, an insider enrichment vehicle masquerading as a uranium development company,” the firm said, while estimating that insiders and their affiliates have sold $275 million in stock in the past 3 years alone.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NXE">NXE stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume remained at ‘normal’ levels.NXE has gained over 60% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-healthcare-triangle-stock-plummet-today/cZbFkc4R4FW">Why Did Healthcare Triangle Stock Plummet 20% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Located in the uranium-rich Athabasca Basin, NexGen Energy's Rook 1 project proposes an underground mine and mill near the Arrow Deposit. | Source: Nexgen Energy

NXE Stock Tumbles After Culper Research Reveals Short Position

Culper alleged that the net present value of NexGen’s Rook I project is overstated by 43% to 62% and the company is “ultimately an insider enrichment scheme with substantial downside.”

Equity

Culper alleged that the net present value of NexGen’s Rook I project is overstated by 43% to 62% and the company is “ultimately an insider enrichment scheme with substantial downside.”


NexGen Energy Ltd. engages in the acquisition, exploration and development of uranium properties. Its uranium project portfolio includes Arrow, South Arrow, Harpoon, Bow, IsoEnergy, SW1, SW2, SW3, and IsoEnergy properties. The company was founded by Leigh B. Curyer on March 8, 2011 and is headquartered in Vancouver, Canada.

Current Price	$12.38
Prev Close	$12.34
Open	$12.42
Dividend Yield	0.00%
50-Day Moving Average	$10.92
Beta	1.47
Avg. Volume	8.85M
PE Ratio	-29.52

52-Week High	$13.96
52-Week Low	$3.91
Market Capitalization	$8.1B
EPS (Annual)	-$0.1021
Price to Book	10.78
Revenue Per Employee	$0.00

NXE
NexGen Energy Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NXE News

NXENexGen Energy Ltd